Tag Archives: Michael Higgins
Zynerba Pharmaceuticals (ZYNE) Receives a Buy from Ladenburg Thalmann & Co.
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report), with a price target of $26. The company’s shares closed last Monday at $8.95. Higgins noted: “We
Rhythm Pharmaceuticals Inc (RYTM) Gets a Buy Rating from Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Rhythm Pharmaceuticals Inc (RYTM – Research Report) today and set a price target of $43. The company’s shares closed last Monday at $21.08. Higgins said: “We’ve learned from
Cerecor Inc (CERC) Received its Third Buy in a Row
After H.C. Wainwright and Maxim Group gave Cerecor Inc (NASDAQ: CERC) a Buy rating last month, the company received another Buy, this time from Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on Cerecor Inc today and
Armata Pharmaceuticals Inc (ARMP) Gets a Buy Rating from Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Armata Pharmaceuticals Inc (ARMP – Research Report) on August 19 and set a price target of $9. The company’s shares closed last Monday at $4.40, close to its
Novus Therapeutics, Inc. (NVUS) Gets a Buy Rating from Ladenburg Thalmann & Co.
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Novus Therapeutics, Inc. (NVUS – Research Report), with a price target of $10. The company’s shares closed last Monday at $0.79, close to
Intec Pharma Ltd (NTEC) Receives a Hold from Ladenburg Thalmann & Co.
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Hold rating on Intec Pharma Ltd (NTEC – Research Report), with a price target of $0.50. The company’s shares closed on Friday at $0.46, close to
